CeeNU: profile and news

Zanosar® Superior to Doxorubicin for Advanced Carcinoid Tumors Aug 2, 2005
Chemotherapy response rates are low and some of the agents studied include 5-fluorouracil, BiCNU® (carmustine), CeeNU® (lomustine), doxorubicin, dacarbazine ... - Cancer Consultants (press release)

Other information

Indication
For use as a single agent in addition to other treatment modalities to treat brain tumors and Hodgkin's disease

Pharmacology
Although it is generally agreed that CeeNU alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Mechanism Of Action
Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents

Drug Category
Antineoplastic Agents; ATC:L01AD02

Brand Names/Synonyms
Belustine; CCNU; CCRIS 860; CHEMBANK4359; Ccnu [Chloroethyl Nitrosoureas]; Cecenu; Ceenu; Ceenu®; Chloroethylcyclohexylnitrosourea; Cinu; Cyclohexyl Chloroethyl Nitrosourea; HSDB 6519; ICIG 1109; Lomustina [Inn-Spanish]; Lomustine; Lomustine [Usan:Ban:Inn]; Lomustinum [Inn-Latin]; RB 1509; SRI 2200; [Inn-Spanish]

Dosage Forms
CAPSULES

Absorption
Rapidly and completely absorbed (in 30-60 minutes)

Interactions
Interactions for Lomustine:

No Information Provided.

Chemical IUPAC Name
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea

Chemical Formula
C9H16ClN3O2

Half Life
16 hours-2 days

Drug Type
Approved Drug

# Accession No
APRD00292

CAS Registry Number
13010-47-4